Want to see IN:AJANTPHARM full AI Analyst Report?
AJANTPHARM Stock Chart & Stats
₹3366.45
₹16.60(0.49%)
At close: 4:00 PM EDT
₹3366.45
₹16.60(0.49%)
Day’s Range― - ―
52-Week Range₹2,335.00 - ₹3,796.95
Previous CloseN/A
Volume81.90K
Average Volume (3M)2.10K
Market Cap
₹458.06B
Enterprise Value₹346.33K
Total Cash (Recent Filing)₹6.65B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)40.1
Beta0.44
Next Earnings
Nov 04, 2026EPS Estimate
23.05Next Dividend Ex-DateN/A
Dividend Yield1.65%
Share Statistics
EPS (TTM)90.84
Shares Outstanding124,959,020
10 Day Avg. Volume2,991
30 Day Avg. Volume2,099
Financial Highlights & Ratios
PEG Ratio2.23
Price to Book (P/B)7.74
Price to Sales (P/S)6.43
P/FCF Ratio231.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)100.21
Revenue Forecast (FY)₹62.86B
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth And ProfitabilitySustained revenue expansion alongside strong net and operating margins indicates solid product demand, pricing capability and cost control. This supports durable earnings quality, provided the company can stabilize the recent margin decline.
Conservative Balance Sheet And Strong ReturnsLow leverage gives Ajanta Pharma financial flexibility to fund product development, manufacturing and market expansion without excessive financing risk. Consistently strong ROE also indicates effective use of shareholder capital and a resilient operating model.
Diversified Branded-generics PlatformExposure to multiple therapeutic areas and both domestic and international markets reduces dependence on a single product, geography or disease segment. Its branded-generics model can support recurring demand through established portfolios and physician adoption.
Bears Say
Recent Margin CompressionThe margin decline may reflect unfavorable product mix, pricing pressure or higher input costs. If persistent, it could reduce operating leverage and weaken earnings growth even if revenue continues expanding, making margin recovery important for durable profitability.
Weaker Cash-flow ConversionCash generation has become less predictable than reported earnings, potentially due to working-capital swings or higher cash investment. Prolonged weak conversion could constrain reinvestment capacity and make internally funded growth less dependable.
Debt Has Increased From Prior YearsThe balance sheet remains conservative, but the recent debt uptick warrants monitoring because it could signal greater funding needs or investment intensity. Further increases would gradually reduce financial flexibility and raise sensitivity to execution or cash-flow setbacks.
Ajanta Pharma Limited News
AJANTPHARM FAQ
What was Ajanta Pharma Limited’s price range in the past 12 months?
Ajanta Pharma Limited lowest stock price was ₹2335.00 and its highest was ₹3796.95 in the past 12 months.
What is Ajanta Pharma Limited’s market cap?
Ajanta Pharma Limited’s market cap is ₹458.06B.
When is Ajanta Pharma Limited’s upcoming earnings report date?
Ajanta Pharma Limited’s upcoming earnings report date is Nov 04, 2026 which is in 73 days.
How were Ajanta Pharma Limited’s earnings last quarter?
Ajanta Pharma Limited released its earnings results on Jul 30, 2026. The company reported ₹26.72 earnings per share for the quarter, beating the consensus estimate of ₹23.04 by ₹3.68.
Is Ajanta Pharma Limited overvalued?
According to Wall Street analysts Ajanta Pharma Limited’s price is currently Overvalued.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 1.65%. See more information on Ajanta Pharma Limited dividends here
What is Ajanta Pharma Limited’s EPS estimate?
Ajanta Pharma Limited’s EPS estimate is 23.05.
How many shares outstanding does Ajanta Pharma Limited have?
Ajanta Pharma Limited has 124,959,020 shares outstanding.
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Ajanta Pharma Limited reported an EPS of ₹26.72 in its last earnings report, beating expectations of ₹23.04. Following the earnings report the stock price went up 0.935%.
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
Currently, no hedge funds are holding shares in IN:AJANTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ajanta Pharma Limited
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
―
Wockhardt Limited
―